Tests stool protein markers to help diagnose inflammatory bowel disease
Tests protein signatures in stool to detect active Crohn's disease or ulcerative colitis in adults.
Plain-language title generated from the registry record
Registry title: Assessment of Non-invasive Tools for Detecting Active Inflammatory Bowel Disease
Key facts
- Where
- Sherbrooke, CanadaSee the site
Where in Canada
- Centre de recherche of the CIUSSS de l'Estrie-CHUSSherbrooke, CanadaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Jean-François Beaulieu
- Trial code
- NCT06722456
- Record updated
- 9 December 2024
- Original description
Part of the success of the treatment of people living with inflammatory bowel diseases (IBD) depends on the information that the doctor can obtain from the different clinical tests. Some of these tests are invasive such as the colonoscopy but other such the fecal calprotectin test, which measures intestinal inflammation, are non-invasive and useful to evaluate the success of the treatments. Unfortunately, the results from the non-invasive tests are not always clear and need to be complete with invasive tests for the right diagnosis.Read full original descriptionShow less
Set-up of Mass Spectrometry-based Stool Tests for Improving the Diagnosis and Management of Inflammatory Bowel Disease
Part of the success of the treatment of people living with inflammatory bowel diseases (IBD) depends on the information that the doctor can obtain from the different clinical tests. Some of these tests are invasive such as the colonoscopy but other such the fecal calprotectin test, which measures intestinal inflammation, are non-invasive and useful to evaluate the success of the treatments. Unfortunately, the results from the non-invasive tests are not always clear and need to be complete with invasive tests for the right diagnosis.
The aim of this research is to test new stool markers for assisting the gastroenterologist to diagnose inflammatory bowel conditions including Crohn's disease (CD) and ulcerative colitis (UC) and to carefully monitoring the effects of medications on remission. We are using applications based on the use of mass spectrometry for identifying the proteins that are released by the host in the stools. We have identified more than 400 proteins in total. Based on informatics, we have been able to produce lists of unique stool proteins that can rapidly inform the doctor if the person has an IBD, whether it is a CD or an UC and, more importantly for the treatment, if the IBD is active or in remission.
The purpose of this study is to validate these protein markers in a blind test, where the real diagnosis will only be revealed after the analysis of the samples.
This study will bring a new power tool to assist the gastroenterologist in the treatment of people living with IBD.
Inclusion: Be affected with one of the two main inflammatory bowel diseases (Crohn's disease of ulcerative colitis); Be invited to participate on the base of a routine follow up by their gastroenterologist; Be scheduled for a calprotectin test and a colonoscopy; Accept to participate and provide an extra stool sample for analysis.
Exclusion: Having no history of inflammatory bowel disease; Be affected with an history of gastrointestinal disease other than Crohn disease or ulcerative colitis.